New combo shows promise in tough pancreatic cancer trial
NCT ID NCT05546853
First seen Feb 06, 2026 · Last updated May 20, 2026 · Updated 12 times
Summary
This early-phase study tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study involved 43 participants and focused on side effects and how well the tumor responded. The goal was to improve tumor shrinkage and survival without causing too many extra side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HP Pitié Salpetrière
Paris, 75013, France
-
CHRU Lille
Lille, 59037, France
-
CHU Poitiers
Poitiers, 86000, France
-
CHU Rennes
Rennes, 35033, France
-
CHU St Etienne
Saint-Etienne, 42055, France
-
CHU de BORDEAUX
Bordeaux, 33404, France
-
CHU de GRENOBLE ALPES
Grenoble, Alpes, 38043, France
-
CHU de REIMS
Reims, 51092, France
-
Hôpital Privé Jean Mermoz
Lyon, 69008, France
Conditions
Explore the condition pages connected to this study.